iShares Biotechnology ETF (IBB)

NASD · US Equities - Industry Sector · USA

Are the companies inside IBB undervalued?

The companies inside IBB trade 47% above what we estimate they are worth. We could give a verdict on 81% of the fund's weight: 252 holdings as reported to the SEC at 30 Jun 2026.

Where the money is: 6% in companies in the buy zone, 4% about fairly valued, 71% overvalued, 20% without a verdict.

What does IBB hold?

The ten largest holdings, with our verdict on each:

How much does the IBB fee cost?

Its expense ratio is 0.44% a year: on $10,000 held flat that is $440 over 10 years and $880 over 20.

Browse

Other US Equities - Industry Sector ETFs